Terumo India, the Indian subsidiary of Terumo Corporation based in Japan, has recently introduced Ultimaster Nagomi, a Drug-Eluting Stent designed for addressing coronary artery disease. In India, where cardiovascular disease accounts for 25% of all fatalities, affecting approximately 54.5 million people, this launch aims to contribute to the medical technology advancements in the field.

Specialized stents known as drug-eluting stents (DES) are specifically designed for treating coronary artery disease. Ongoing investments are directed toward the development of next-generation stents aimed at improving the safety and efficacy of treatments for coronary artery conditions.

Terumo India's Ultimaster Nagomi represents an advanced generation of Drug-Eluting Stents, characterized by its ability to navigate complex arteries seamlessly and adapt effortlessly to various vessel sizes. The optimal design of Ultimaster Nagomi allows for effective use in both small and large coronary arteries, offering a tailored stent selection option for a broader range of patients.

Mr. Shishir Agarwal, President and Managing Director of Terumo India, expressed, "Ultimaster Nagomi embodies the legacy of Japanese technology, supported by robust clinical evidence from the Ultimaster family across various procedures. Our goal is to introduce cutting-edge Japanese technologies to benefit all Indian patients, allowing them access to the latest innovations in healthcare".

Elaborating on the need, Mr. Nitin Stephen Abel, Director of Terumo Intervention Systems India, said, "Over the years, DES has evolved to become a preferred option for heart-related treatments. Given the rising occurrences of cardiovascular diseases, continuous advancements in treatment methods are essential. The introduction of Ultimaster Nagomi will be a notable development for the cardiac care ecosystem in India".